Global Information
회사소개 | 문의 | 비교리스트

세계의 갑상선 질환 시장 : 예측

Global Thyroid Disorder Market Research Report Forecast to 2022

리서치사 Market Research Future
발행일 2019년 04월 상품 코드 851696
페이지 정보 영문 118 Pages
가격
US $ 4,450 ₩ 5,371,000 Unprintable PDF (Single User License)
US $ 6,250 ₩ 7,543,000 Printable PDF (Corporate User License)


세계의 갑상선 질환 시장 : 예측 Global Thyroid Disorder Market Research Report Forecast to 2022
발행일 : 2019년 04월 페이지 정보 : 영문 118 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 갑상선 질환(Thyroid Disorder) 시장을 분석했으며, 제품 개요와 시장이 기본 구조, 주요 시장 성장 촉진요인 및 억제요인, 전체적인 시장 동향 전망(과거 3년간, 향후 5년간), 종류별·치료 방법별·투여 경로별·최종사용자별·지역별 상세 동향, 시장 점유율 구조, 주요 기업 개요·실적·전략 등의 정보를 정리하여 전해드립니다.

제1장 주요 요약

제2장 분석 개요

제3장 시장 개요

제4장 분석 방법

제5장 시장 역학

  • 개요
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 거시경제 지표

제6장 시장 요인 분석

  • Porter's Five Forces 분석

제7장 세계의 갑상선 장애 시장 : 종류별

  • 개요
    • 서론
    • 갑상선 기능 저하증
    • 갑상선 기능 항진증

제8장 세계의 갑상선 장애 시장 : 치료법별

  • 개요
    • 서론
    • 약물치료
    • 방사선옥소요법
    • 외과수술

제9장 세계의 갑상선 장애 시장 : 투여경로별

  • 개요
    • 경구 투여
    • 정맥내 투여

제10장 세계의 갑상선 장애 시장 : 최종사용자별

  • 개요
    • 병원
    • 클리닉

제11장 세계의 갑상선 장애 시장 : 지역별

  • 개요
  • 아메리카(북미(미국, 캐나다), 남미)
  • 유럽(서유럽(독일, 프랑스, 영국, 이탈리아, 스페인 등), 동유럽)
  • 아시아태평양(일본, 중국, 인도, 한국, 호주 등)
  • 중동 및 아프리카

제12장 경쟁 환경

  • 기업별 시장 점유율 분석
    • 서론

제13장 기업 개요

  • Pfizer Inc
    • 기업 개요
    • 재무 개요
    • 주요 제품/서비스
    • 최근의 주요 동향
    • SWOT 분석
    • 주요 전략
  • Allergan Inc.
  • AbbVie Inc.
  • Merck KGaA
  • RLC Labs
  • Abbott Laboratories
  • GlaxoSmithKline Plc
  • Mylan

제14장 부록

LSH 19.06.07

List of Tables

  • TABLE 1 MARKET SYNOPSIS
  • TABLE 2 LIST OF ASSUMPTIONS
  • TABLE 3 GLOBAL THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 4 GLOBAL THYROID DISORDER MARKET FOR HYPOTHYROIDISM, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 5 GLOBAL THYROID DISORDER MARKET FOR HYPERTHYROIDISM, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 6 GLOBAL THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 7 GLOBAL THYROID DISORDER MARKET FOR MEDICATIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 8 GLOBAL THYROID DISORDER MARKET FOR RADIOACTIVE IODINE THERAPY, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 9 GLOBAL THYROID DISORDER MARKET FOR SURGERY, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 10 GLOBAL THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 11 GLOBAL THYROID DISORDER MARKET FOR ORAL, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 12 GLOBAL THYROID DISORDER MARKET FOR INTRAVENOUS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 13 GLOBAL THYROID DISORDER MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 14 GLOBAL THYROID DISORDER MARKET FOR HOSPITALS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 15 GLOBAL THYROID DISORDER MARKET FOR CLINICS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 16 GLOBAL THYROID DISORDER MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 17 AMERICAS: THYROID DISORDER MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 18 AMERICAS: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 19 AMERICAS: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 20 AMERICAS: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 21 AMERICAS: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 22 NORTH AMERICA: THYROID DISORDER MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 23 NORTH AMERICA: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 24 NORTH AMERICA: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 25 NORTH AMERICA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 26 NORTH AMERICA: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 27 US: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 28 US: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 29 US: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 30 US: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 31 CANADA: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 32 CANADA: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 33 CANADA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 34 CANADA: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 35 SOUTH AMERICA: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 36 SOUTH AMERICA: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 37 SOUTH AMERICA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 38 SOUTH AMERICA: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 39 EUROPE: THYROID DISORDER MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 40 EUROPE: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 41 EUROPE: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 42 EUROPE: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 43 EUROPE: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 44 WESTERN EUROPE: THYROID DISORDER MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 45 WESTERN EUROPE: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 46 WESTERN EUROPE: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 47 WESTERN EUROPE: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 48 WESTERN EUROPE: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 49 GERMANY: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 50 GERMANY: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 51 GERMANY: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 52 GERMANY: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 53 FRANCE: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 54 FRANCE: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 55 FRANCE: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 56 FRANCE: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 57 UK: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 58 UK: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 59 UK: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 60 UK: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 61 ITALY: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 62 ITALY: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 63 ITALY: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 64 ITALY: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 65 SPAIN: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 66 SPAIN: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 67 SPAIN: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 68 SPAIN: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 69 REST OF WESTERN EUROPE: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 70 REST OF WESTERN EUROPE: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 71 REST OF WESTERN EUROPE: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 72 REST OF WESTERN EUROPE: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 73 EASTERN EUROPE: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 74 EASTERN EUROPE: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 75 EASTERN EUROPE: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 76 EASTERN EUROPE: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 77 ASIA-PACIFIC: THYROID DISORDER MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 78 ASIA-PACIFIC: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 79 ASIA-PACIFIC: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 80 ASIA-PACIFIC: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 81 ASIA-PACIFIC: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 82 JAPAN: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 83 JAPAN: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 84 JAPAN: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 85 JAPAN: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 86 CHINA: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 87 CHINA: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 88 CHINA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 89 CHINA: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 90 INDIA: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 91 INDIA; THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 92 INDIA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 93 INDIA: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 94 REPUBLIC OF KOREA: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 95 REPUBLIC OF KOREA: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 96 REPUBLIC OF KOREA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 97 REPUBLIC OF KOREA: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 98 AUSTRALIA: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 99 AUSTRALIA: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 100 AUSTRALIA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 101 AUSTRALIA: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 102 REST OF ASIA-PACIFIC: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 103 REST OF ASIA-PACIFIC: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 104 REST OF ASIA-PACIFIC: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 105 REST OF ASIA-PACIFIC: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 106 MIDDLE EAST AND AFRICA: THYROID DISORDER MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 107 MIDDLE EAST AND AFRICA: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 108 MIDDLE EAST AND AFRICA: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 109 MIDDLE EAST AND AFRICA: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 110 MIDDLE EAST AND AFRICA: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 111 MIDDLE EAST: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 112 MIDDLE EAST: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 113 MIDDLE EAST: THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 114 MIDDLE EAST: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)
  • TABLE 115 AFRICA: THYROID DISORDER MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 116 AFRICA: THYROID DISORDER MARKET, BY TREATMENT, 2015-2022 (USD MILLION)
  • TABLE 117 AFRICA; THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 118 AFRICA: THYROID DISORDER MARKET, BY END USER 2015-2022 (USD MILLION)

List of Figures

  • FIGURE 1 GLOBAL THYROID DISORDER MARKET: MARKET STRUCTURE
  • FIGURE 2 RESEARCH PROCESS OF MRFR
  • FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACHES
  • FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL THYROID DISORDER MARKET
  • FIGURE 5 DRIVERS IMPACT ANALYSIS: GLOBAL THYROID DISORDER MARKET
  • FIGURE 6 RESTRAINTS IMPACT ANALYSIS: GLOBAL THYROID DISORDER MARKET
  • FIGURE 7 PORTER'S FIVE FORCES MODEL: GLOBAL THYROID DISORDER MARKET
  • FIGURE 8 GLOBAL THYROID DISORDER MARKET, BY TYPE, 2017 (% SHARE)
  • FIGURE 9 GLOBAL THYROID DISORDER MARKET, BY TYPE, 2017 & 2022
  • FIGURE 10 GLOBAL THYROID DISORDER MARKET, BY TREATMENT, 2017 (% SHARE)
  • FIGURE 11 GLOBAL THYROID DISORDER MARKET, BY TREATMENT, 2017 & 2022
  • FIGURE 12 GLOBAL THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2017 (% SHARE)
  • FIGURE 13 GLOBAL THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2017 & 2022
  • FIGURE 14 GLOBAL THYROID DISORDER MARKET, BY END USER, 2017 (% SHARE)
  • FIGURE 15 GLOBAL THYROID DISORDER MARKET, BY END USER, 2017 & 2022
  • FIGURE 16 GLOBAL THYROID DISORDER MARKET, BY REGION, 2017 & 2022 (USD MILLION)
  • FIGURE 17 GLOBAL THYROID DISORDER MARKET, BY REGION, 2017 (% SHARE)
  • FIGURE 18 AMERICAS: THYROID DISORDER MARKET SHARE, BY REGION, 2017
  • FIGURE 19 EUROPE: THYROID DISORDER MARKET SHARE, BY REGION, 2017 (%)
  • FIGURE 20 ASIA-PACIFIC: THYROID DISORDER MARKET SHARE, BY COUNTRY, 2017 (%)
  • FIGURE 21 MIDDLE EAST AND AFRICA: THYROID DISORDER MARKET SHARE, BY REGION, 2017 (%)
  • FIGURE 22 GLOBAL THYROID DISORDER MARKET, MARKET SHARE ANALYSIS 2017 (% SHARE)

Introduction

Thyroid disorders may lead to elevated or decreased levels of metabolic hormones, leading to medical conditions such as hypothyroidism, hyperthyroidism, etc. falling under the category of thyroid disorders. The global thyroid disorder market is estimated to be driven by the increasing prevalence of thyroid diseases, raising awareness of the disease, and favorable reimbursement and funding policies. According to the Thyroid Disease: Assessment and Management Draft of the National Institute for Health and Care Excellence published in 2017, hypothyroidism was estimated to be prevalent in 27.2% of the total UK population. Such prevalence of thyroid disorders provides suitable backgrounds for the market to grow.

However, factors such as the high cost of treatment procedures such as radioactive iodine (RAI) therapy and side-effects related to the available therapeutic restrain the market growth.

The global thyroid disorder market is expected to reach USD 2,914.93 by 2022 from USD 2,442.47 million in 2017 and is expected to register a CAGR of 3.60% during the forecast period of 2018 to 2022.

In 2017, the market was led by the Americas with a 47.2% share, followed by Europe and Asia-Pacific with shares of 30.6% and 17.3%, respectively. The market growth in the Americas is attributed to the increasing prevalence of thyroid disorders and a rise in risk factors such as obesity and diabetes.

The global thyroid disorder market has been segmented based on type, treatment, route of administration, end user, and region.

The global thyroid disorder market, on the basis of type, has been segmented into hypothyroidism and hyperthyroidism.

The global thyroid disorder market, by treatment, has been segmented into medications, radioactive iodine therapy, and surgery.

The global thyroid disorder market, by route of administration, has been segmented into oral, intravenous, and others.

The market based on end user has been segmented into hospitals, clinics, and others.

Key Players

Pfizer Inc, Allergan, AbbVie Inc., Merck KGaA, RLC Labs, GlaxoSmithKline Plc, and Mylan

Study Objectives

  • To provide a comprehensive analysis of the industry and its sub-segments in the global market, thereby providing a detailed structure of the industry
  • To provide detailed insights into factors driving and restraining the growth of the global thyroid disorder market
  • To estimate the market size of thyroid disorder from 2015 to 2022 for different regions. Wherein, 2015 to 2016 would be the historic period, 2017 shall be the base year, and 2018 to 2022 will be the forecast period for the study
  • To analyze the global thyroid disorder market, on the basis of four main regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa
  • To compare products with respect to various players in the market
  • To provide country-wise market value analysis for various segments of the thyroid disorder market
  • To provide strategic profiling of key companies (manufacturers and distributors) present across the globe and comprehensively analyze their competitiveness/competitive landscape in this market
  • To provide distribution chain analysis/value chain for the thyroid disorder market

Target Audience

  • Pharmaceutical Manufacturing Companies
  • Biotechnology Companies
  • Government Research Institutes
  • Academic Institutes and Universities

Key Findings

  • The global thyroid disorder market is expected to reach USD 2,914.93 million by 2022 from USD 2,442.47 million in 2017 and is expected to register a CAGR of 3.60% during the forecast period of 2018 to 2022
  • On the basis of product type, the continuous-wave (CW) thyroid disorder segment accounted for the largest market share and is projected to register a CAGR of 8.67% from 2018 to 2022
  • Based on type, the hypothyroidism segment accounted for the largest market share and is anticipated to register a CAGR of 3.50% from 2018 to 2022
  • Based on treatment, the medications segment accounted for the largest market share and is anticipated to register a CAGR of 3.71% from 2018 to 2022
  • Based on route of administration, the oral segment accounted for the largest market share and is anticipated to register a CAGR of 3.64%% from 2018 to 2022
  • Based on end user, the hospitals segment held the largest market share of 55.7% in 2017 and is projected to register a CAGR of 3.89% during the forecast period
  • The Americas is expected to hold the largest share of the global thyroid disorder market at a CAGR of 3.50% from 2018 to 2022
  • Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 4.01% from 2018 to 2022

Regional Analysis

  • Americas
    • North America
  • US
  • Canada
    • South America
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • Middle East
    • Africa

Table of Contents

1 Report Prologue

2 Executive Summary

3 Market Introduction

  • 3.1 Definition
  • 3.2 Scope of the Study
  • 3.3 List of Assumptions
  • 3.4 Market Structure

4 Research Methodology

  • 4.1 Research Process
  • 4.2 Primary Research
  • 4.3 Secondary Research
  • 4.4 Market Size Estimation
  • 4.5 Forecast Model

5 Market Dynamics

  • 5.1 Introduction
  • 5.2 Drivers
    • 5.2.1 Increasing prevalence of thyroid diseases
    • 5.2.2 Rising awareness of thyroid
    • 5.2.3 Favorable reimbursement and funding policies
    • 5.2.4 Drivers Impact Analysis
  • 5.3 Restraint
    • 5.3.1 High cost of treatment procedures such as radioactive iodine (RAI) therapy
    • 5.3.2 Side-effects related to available therapeutics
    • 5.3.3 Restraints Impact Analysis
  • 5.4 Opportunity
    • 5.4.1 Emerging markets of Asia-Pacific
  • 5.5 Macroeconomic Indicators

6 Market Factor Analysis

  • 6.1 Porter's Five Forces Model
    • 6.1.1 Threat of New Entrants
    • 6.1.2 Bargaining Power of Suppliers
    • 6.1.3 Threat of Substitutes
    • 6.1.4 Bargaining Power of Buyers
    • 6.1.5 Intensity of Rivalry

7 Global Thyroid Disorder Market, by Type

  • 7.1 Overview
    • 7.1.1 Introduction
    • 7.1.2 Hypothyroidism
    • 7.1.3 Hyperthyroidism

8 Global Thyroid Disorder Market, by Treatment

  • 8.1 Overview
    • 8.1.1 Introduction
    • 8.1.2 Medications
    • 8.1.3 Radioactive Iodine Therapy
    • 8.1.4 Surgery

9 Global Thyroid Disorder Market, by Route of Administration

  • 9.1 Overview
    • 9.1.1 Oral
    • 9.1.2 Intravenous

10 Global Thyroid Disorder Market, by End User

  • 10.1 Overview
    • 10.1.1 Hospitals
    • 10.1.2 Clinics

11 Global Thyroid Disorder Market, by Region

  • 11.1 Overview
  • 11.2 Americas
    • 11.2.1 North America
      • 11.2.1.1 US
      • 11.2.1.2 Canada
    • 11.2.2 South America
  • 11.3 Europe
    • 11.3.1 Western Europe
      • 11.3.1.1 Germany
      • 11.3.1.2 France
      • 11.3.1.3 UK
      • 11.3.1.4 Italy
      • 11.3.1.5 Spain
      • 11.3.1.6 Rest of Western Europe
    • 11.3.2 Eastern Europe
  • 11.4 Asia-Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Republic of Korea
    • 11.4.5 Australia
    • 11.4.6 Rest of Asia-Pacific
  • 11.5 Middle East & Africa
    • 11.5.1 Middle East
    • 11.5.2 Africa

12 Competitive Landscape

  • 12.1 Company Market Share Analysis
    • 12.1.1 Introduction

13 Company Profiles

  • 13.1 Pfizer Inc
    • 13.1.1 Company Overview
    • 13.1.2 Financial Overview
    • 13.1.3 Products/Services Offered
    • 13.1.4 Key Developments
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Strategy
  • 13.2 Allergan Inc.
    • 13.2.1 Company Overview
    • 13.2.2 Financial Overview
    • 13.2.3 Products/Services Offered
    • 13.2.4 Key Developments
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key strategy
  • 13.3 AbbVie Inc.
    • 13.3.1 Company Overview
    • 13.3.2 Financial Overview

Source: Annual Report, Press Releases, MRFR Analysis 104

    • 13.3.3 Products/Services Offering
    • 13.3.4 Key Developments
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Strategy
  • 13.4 Merck KGaA
    • 13.4.1 Company Overview
    • 13.4.2 Financial Overview

Source: Annual Report, Press Releases, MRFR Analysis 106

    • 13.4.3 Products/Services Offering
    • 13.4.4 Key Developments
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Strategy
  • 13.5 RLC Labs
    • 13.5.1 Company Overview
    • 13.5.2 Financial Overview
    • 13.5.3 Products/Services Offered
    • 13.5.4 SWOT Analysis
    • 13.5.5 Key Developments
    • 13.5.6 Key strategy
  • 13.6 Abbott Laboratories
    • 13.6.1 Company Overview
    • 13.6.2 Financial Overview
    • 13.6.3 Products/Services Offered
    • 13.6.4 Key Developments
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Strategy
  • 13.7 GlaxoSmithKline Plc
    • 13.7.1 Company Overview
    • 13.7.2 Financial Overview
    • 13.7.3 Products/Services Offered
    • 13.7.4 Key Developments
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Strategy
  • 13.8 Mylan
    • 13.8.1 Company Overview
    • 13.8.2 Financial Overview
    • 13.8.3 Products/Services Offered
    • 13.8.4 Key Developments
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Strategy

14 Appendix

  • 14.1 Discussion Blue Print
Back to Top
전화 문의
F A Q